問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Radiation Therapy

Division of General Surgery

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2024-06-04

陳偉武Chen, Wei-Wu
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

  • tomwchen@ntuh.gov.tw

Recruiting Trial

128Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳偉武

List

221Cases

2020-07-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-08-01 - 2025-07-01

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Not yet recruiting1Sites

2020-08-17 - 2023-12-12

Phase I/II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-10-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2020-10-15 - 2027-09-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2020-10-15 - 2026-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting7Sites

2020-11-01 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2020-12-01 - 2028-12-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2021-01-01 - 2025-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting3Sites

2018-05-02 - 2022-01-20

Phase III

Completed
A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with HerceptinR as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer

  • Condition/Disease

    Metastatic Prostate Cancer

  • Test Drug

    EG12014

Participate Sites
8Sites

Recruiting6Sites

劉良智
China Medical University Hospital-Taipei

未分科

陳訓徹
Linkou Chang Gung Medical Foundation

1 2 3 4 5 23
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB